A botulism outbreak linked to ByHeart formula threatens infant health across 19 states, raising alarms about product safety and manufacturer accountability.
Story Highlights
- Over 50 infants in 19 states affected by botulism linked to ByHeart formula.
- FDA and CDC investigations expand scope to all ByHeart products since 2022.
- ByHeart recalls all U.S. products amid contamination concerns.
- Families of affected infants file lawsuits against the company.
- Botulism, rare but serious, prompts scrutiny of manufacturing practices.
Infant Health at Risk: The Botulism Outbreak
Federal health officials have identified an alarming outbreak of infant botulism associated with ByHeart baby formula, affecting at least 51 infants across 19 states.
The U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) have broadened their investigation to encompass all ByHeart products since the company began production in March 2022.
This expansion follows concerns that contamination might have affected all formulas produced by the company.
ByHeart, a manufacturer of organic infant formula based in New York, initiated a complete recall of its products on November 11, 2025. This decision comes as the company faces scrutiny over potential contamination issues dating back to its inception.
ByHeart, which held approximately 1% of the U.S. infant formula market, has been cooperating with federal investigations to determine the contamination’s root cause.
Parents like Andi Galindo and Amy Mazziotti, whose children were hospitalized with botulism after consuming ByHeart formula, are demanding accountability.
The expanding investigation now includes cases dating back to the product’s market debut. Both mothers express mixed feelings of relief and frustration, as their longstanding suspicions about the formula’s safety are validated by the latest findings.
Federal health officials have expanded an outbreak of infant botulism tied to recalled ByHeart baby formula to include all illnesses reported since the company began production in March 2022.
Read more: https://t.co/ryz33MhBUW pic.twitter.com/wHxlsjxsEB
— ABC News (@ABC) December 11, 2025
Historical Issues and Regulatory Failures
The current crisis is not the first time ByHeart has faced issues related to contamination. In 2022, the company recalled five batches of infant formula after a sample tested positive for cronobacter sakazakii at a packaging plant.
In 2023, further problems were unearthed, including mold, water leaks, and insects at a Pennsylvania facility, leading to its closure. These recurring issues highlight a troubling pattern of regulatory oversight failures and inadequate manufacturing practices.
Despite these challenges, ByHeart insists on its cooperation with federal agencies. The company’s efforts to address the contamination include extensive testing and coordination with FDA inspectors visiting their production sites in Iowa and Oregon.
However, the lack of transparency and delayed response continues to fuel public concern, especially as the number of affected infants rises.
The Broader Implications for Infant Formula Safety
Infant botulism, although rare, poses significant health risks to babies under one year old. The disease results from ingesting bacteria that produce spores in the intestines, leading to a potentially fatal toxin.
The situation has prompted a renewed examination of safety standards in the infant formula industry, as no previous outbreaks of botulism linked to powdered formula had been confirmed.
Legal actions have surged as families affected by the outbreak seek compensation for medical expenses and emotional distress. These lawsuits allege that ByHeart was negligent in ensuring the safety of its products.
The unfolding legal battle underscores the critical importance of rigorous safety protocols and accountability in protecting consumer health.
